Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union. The company develops Nidlegy which is in Phase III clinical trial for the treatment of advanced melanoma and Phase II clinical trial for the treatment of basal cell carcinoma and cutaneous squamous cell carcinoma; Fibromun which is in Phase III clinical trial for the treatment of soft-tissue sarcoma and Phase II clinical trial for the treatment of glioblastoma; Darleukin which is in Phase II clinical trial for the treatment of non-small cell lung cancer; Dekavil which is in Phase II clinical trial for the treatment of chronic inflammatory disorders; and Dodekin which is in Phase I clinical trial for the treatment of various solid tumors. It is also involved in the development of small molecule products, including OncoFAP which is in Phase I clinical trial for the treatment of solid tumors; OncoACP3 which is in Phase I clinical trial for the treatment of prostate cancer; and OncoCAIX which is in Phase 1 trial for the treatment of renal cell carcinoma and other hypoxic tumors. The company was founded in 1996 and is headquartered in Sovicille, Italy.…
Philogen S p A : 16 Novembre 2026 – Aggiornamento sul programma di acquisto di azioni proprie
Philogen (BIT: PHIL) is listed on Borsa Italiana, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 230 employees.
The shares were at 20.95 EUR on 20 November 2026, down 9.7% over 52 weeks. Its 52-week range is 19.56 EUR to 26.00 EUR: the price is 19.4% below the high and 7.1% above the low.
At a market capitalisation of 842.44M EUR, it trades at 3.8 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 89% for PHIL. It pays a dividend yielding 3.34% (it pays out 13% of its earnings), against a median of 0.95% among the dividend payers in that peer group.
Philogen reports return on equity of 61.4%, an operating margin of 79.1% and revenue down 52.3% year over year.
It holds more cash than debt, a net cash position of 325.70M EUR. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 3 analysts cover the stock; their mean price target of 28.33 EUR is 35.2% above the current price.
No upcoming events tracked.